Overview

Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study

Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The long-term objective of this study is to test whether the addition of SGLT2 inhibitors to usual care during acute heart failure management in patients who develop kidney injury shortens the time to achieving symptomatic improvement and kidney function recovery. The study aims to assess feasibility and acceptability of such a randomized clinical trial.
Phase:
Phase 2
Details
Lead Sponsor:
Yale University
Collaborator:
American Heart Association
Treatments:
Dapagliflozin